Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AVITA Medical, Inc. (RCEL) SEC filings page brings together the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, annual reports on Form 10-K, and quarterly reports on Form 10-Q. As a therapeutic acute wound care company focused on the RECELL System and related wound care technologies, AVITA Medical uses these filings to report on its financial condition, capital structure, governance, and material business developments.
In its Form 8-K filings, AVITA Medical has disclosed material definitive agreements such as senior secured credit facilities, amendments to existing credit agreements, and related covenants tied to trailing twelve-month revenue. These documents detail loan terms, revenue requirements, warrant issuances, and security interests in company assets. Other 8-K reports cover equity placements, including CHESS Depositary Interests issued to institutional and professional investors, and governance matters such as board appointments, executive transitions, and director compensation arrangements.
Periodic reports like the Form 10-K and Form 10-Q (accessible from this filings stream when available) provide broader information on AVITA Medical’s business, including discussion of its therapeutic acute wound care platform, risk factors, and consolidated financial statements. Investors can review these filings to understand how the company describes its RECELL System, PermeaDerm, and Cohealyx products, as well as its regulatory environment and key risk considerations.
Stock Titan’s platform enhances access to these documents with AI-powered summaries that explain the significance of complex filings, from credit agreements and warrant terms to revenue covenants and equity raises. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K, and Form 4 insider transaction reports are available as they are filed, while AI-generated highlights help readers quickly identify items related to financing, governance, and operational strategy for AVITA Medical.
AVITA Medical, Inc. filed a Current Report on Form 8-K dated August 12, 2025, reporting that the company issued a press release announcing the successful completion of an equity raise in Australia. The filing states the press release is attached as Exhibit 99.1 and clarifies that the information furnished, including the exhibit, is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The 8-K is signed by Chief Financial Officer David O'Toole. The company's common stock trades under the symbol RCEL on Nasdaq.
AVITA Medical, Inc. has filed a Form S-8 to register an additional 2,500,000 shares of common stock under its 2020 Omnibus Incentive Plan following stockholder approval on June 4, 2025. The filing also registers an aggregate of 605,902 shares that are issuable upon exercise or vesting of previously approved awards, comprised of 545,770 stock options and 60,132 restricted stock units.
The registration incorporates by reference prior S-8 filings and recent SEC reports, including the Annual Report for the year ended December 31, 2024 and quarterly reports for the quarters ended March 31, 2025 and June 30, 2025. The filing describes indemnification provisions under Delaware law, charter and bylaw exculpation language, indemnification agreements with directors and officers, and directors' and officers' liability insurance.
AVITA Medical (Nasdaq: RCEL; ASX: AVH) is issuing 400,000 new common shares to two OrbiMed-affiliated lenders in lieu of cash as consideration for a Fifth Amendment to its $40 million secured Credit Agreement. The shares will be delivered on or about 8 Aug 2025; no cash proceeds will be received.
The amendment reduces near-term revenue covenants that trigger mandatory principal amortisation, giving AVITA greater flexibility during FY-25/26 while it scales its FDA-approved RECELL wound-care platform. If future revenue again falls short, the company must repay 5 % of outstanding principal each quarter and pay related fees. Debt remains secured against substantially all assets and is exposed to rising rates.
Following the issue, total basic share count will rise modestly (≈1.5 % based on ~26 M shares outstanding), causing limited dilution. AVITA remains an Emerging Growth Company and does not expect to pay dividends. Key risks disclosed include covenant breach, liquidity pressure, equity volatility and macroeconomic factors.
AVITA Medical, Inc. (RCEL) filed an 8-K announcing a Fifth Amendment to its October 18 2023 Credit Agreement with OrbiMed affiliates. The amendment lowers trailing-12-month revenue covenants for the next four quarters to $73 m (Q3-25), $77 m (Q4-25), $90 m (Q1-26) and $103 m (Q2-26). The original $115 m covenant is reinstated from Q3-26 through the debt’s maturity.
In consideration, the Company will issue 400,000 registered common shares to the lenders, using its effective Form S-3 shelf. All other terms of the credit facility remain unchanged.
Item 2.02 notes release of Q2-25 financial results via Exhibit 99.1, but the filing itself does not include those figures.